Skip to main content

Landos Biopharma, Inc.

LABPDelisted May 23, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001785345

Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.

Q1 2022 vs. Q4 2021

How the institutions holding Landos Biopharma, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of LABP: Q4 2021 compared with Q1 2022
MeasureQ4 2021Of which not filed for Q1 2022Q1 2022Change
Holders40145+6
Shares24.9M40823.9M−1.04M (−4.2%)
Value$119.8M$2.00K$35.3M−$84.5M (−70.6%)

1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (9)

Institutions that held Landos Biopharma, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to LABP in Q1 2022
InstitutionSharesValue% of portfolio
Bridgeway Capital Management, LLC159,000$235.0K0.00%
Jacobs Levy Equity Management, Inc158,875$234.0K0.00%
Millennium Management LLC60,968$90.0K0.00%
D. E. Shaw & Co., Inc.16,988$25.0K0.00%
FMR LLC1,383$2.00K0.00%
Barclays PLC761$1.00K0.00%
Amalgamated Bank802$1.00K0.00%
Advisor Group Holdings, Inc.418$1.00K0.00%
Amalgamated Financial Corp.802$1.00K0.00%

Sold out (3)

Institutions that held Landos Biopharma, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of LABP in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Logos Global Management LP1,375,000$6.60M
Jump Financial, LLC15,200$73.0K
UBS Group AG3,805$18.0K

Not filed for Q1 2022 yet (1)

Institutions that held Landos Biopharma, Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding LABP in Q4 2021 that haven't filed for Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Carroll Financial Associates, Inc.408$2.00K